Elorac announced that the FDA has granted Fast Track designation to its naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma (CTCL). Naloxone is an opiate antagonist with no agonist activity.
Intravenous and subcutaneous formulations of naloxone (Narcan; Endo) have already been approved to treat opiate overdoses. Oral naloxone in combination with buprenorphine (Suboxone; Reckitt Benckiser) has also already been approved to treat opiate dependence.
Currently there are no approved therapeutic treatment options available for pruritus in CTCL. Elorac previously received Orphan Drug Designation for naloxone lotion from the FDA.
For more information call (847) 362-8200 or visit www.eloracpharma.com.